NeuRX Health Inc. Receives Global Manufacturing And Distribution Rights From Davion Healthcare Plc Of Its Breastcheck(TM) Home Test For Breast Anomalies For $120m Usd.

WARWICK, RI / ACCESSWIRE / November 9, 2023 / Rhode Island (USA) based NeuRX Health Inc. a leading medical products and distribution company is pleased to announce they have been granted a Global Manufacturing and Distribution License from Davion Healthcare Plc's a leading medical device manufacturer for their non-invasive BreastCheck™ home test for Breast Anomalies including Breast Cancer.

Both parties have signed binding headline terms with completion of the full license to be filed early January 2024. The agreement sees NeuRX paying Davion the sum of $120 Million USD for the license, together with ongoing royalty payments on global sales of BreastCheck™.

BreastCheck™ is a non-invasive home test for Breast anomalies, including Breast Cancer. The home test takes just fifteen minutes, and the results are immediate. It is registered as a Class1 Medical Device with regulatory authorities in the USA (FDA), Europe (CE) and the United Kingdom (UKCA). BreastCheck™ will be available towards the end of the first quarter 2024 internationally, from Pharmacies, larger Retail Outlets and Online.

"We are thrilled to appoint NeuRX Health Inc. as our global manufacturer and distributor for this important product" said Jack Kaye, Davion's CEO. "The team at NeuRX have extensive experience and expertise in both manufacturing and distribution internationally of medical products"

This licensing agreement follows on from Davion Healthcare's recent announcement of a $30 million IPO fundraising round alongside a NASDAQ listing of the company's ADRs through The Bank of New York Melon, and further supports this process.

NeuRX Health, Inc CEO Robert Hainey said "We are enthusiastic about the prospects this global licensing agreement gives us. Davion's BreastCheck™ product is a global first, for which we expect there will be great demand internationally, and we are excited about the opportunity to manufacture BreastCheck™ in the State Of Rhode Island "

Davion looks forward to a successful IPO and subsequent listing on the NASDAQ stock exchange, which it anticipates will (subject to market forces) take place in the first quarter of 2024. The company remains committed to delivering exceptional value to its shareholders while driving innovation within the medical sector.

Safe Harbor Statement: The information posted in this release may contain forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. You can identify these statements by use of the words "may," "will," "should," "plans," "explores," "expects," "anticipates," "continue," "estimate," "project," "intend," and similar expressions. Forward-looking statements involve risks and uncertainties that could cause actual results to differ materially from those projected or anticipated. These risks and uncertainties include, but are not limited to, general economic and business conditions, effects of continued geopolitical unrest and regional conflicts, competition, changes in technology and methods of marketing, and various other factors beyond the Company's control.

Press inquiries please contact:

info@neurxhealth.com

SOURCE: NeuRX Health Inc.

ACCESSWIRE

News network reaching more than 1,500 media outlets in 98 countries. The newest, fastest-growing and most disruptive newswire available today.